Health
FDA authorizes marketing of new device for short-term treatment of gait deficit in MS patients – News-Medical.Net
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate…
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that consists of a non-implantable apparatus…
-
Noosa News24 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership
-
General24 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
Noosa News15 hours agoNew playground equipment encourages children to learn through ‘risky play’
-
General13 hours agoThree youths in police custody after fire at Ashley Youth Detention Centre in northern Tasmania